Abdominal cramps and high fevers.

2014 Financial Outlook Due to the announced acquisition of Forest Laboratories recently, Inc., Actavis plc programs to provide an updated combined economic forecast for the entire year at or shortly following a close of the acquisition which is expected to occur mid-yr 2014. For the second quarter of 2014, we have assumed extra competition on certain essential products including competition on our generic edition of Lidoderm. We expect second quarter non-GAAP 2014 earnings to be somewhat less than the first quarter 2014. In accordance with applicable Irish and European regulations, our standalone forecast provided at our investor day time on January 31, 2014 is highly recommended withdrawn.